🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06763458
Recruiting Not applicable

Balloon Angioplasty for Minor Unstable Stroke With IntraCranial Atherosclerosis Stenosis (BAMUS-ICAS)

NCT06763458 · tracked via the Priya Life Science China tracker
Sponsor
General Hospital of Shenyang Military Region
Phase
Not applicable
Started
2025-02-19
Last updated
2026-04-27

Condition(s) studied

Ischemic Stroke

Investigational drug(s) / intervention(s)

Submaximal balloon angioplasty

Submaximal balloon angioplasty: The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.

Study summary

Intracranial atherosclerotic stenosis (ICAS) is a common cause of stroke, especially in East and South Asia, and is significantly associated with stroke recurrence and early neurological deterioration (END) despite aggressive medical management. Minor stroke (National Institutes of Health Stroke, NIHSS score ≤ 5) patients with ICAS often has higher risk of END. The early realization of blood flow patency is closely related to the improvement of patient outcomes. Submaximal balloon angioplasty (SBA) as a safer and simpler intervention which can improve cerebral blood flow. Thus, SBA may be an effective strategy for preventing END in acute ischemic stroke patients with ICAS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Over 18 years of age; 2. Minor ischemic stroke within 1 week of onset (NIHSS≤5); 3. Have received the best drug treatment (dual antibody, anti-plate combined with anticoagulation), but symptoms still have measurable fluctuations or progression (NIHSS increased by at least 1 point); 4. Symptoms fluctuate to the time of receiving balloon dilation within 24 hours; 5. The etiology was considered to be severe stenosis of the responsible vessels due to intracranial arteriosclerosis (70-99% stenosis), or perforator artery disease with severe stenosis of the carrier artery (confirmed by MRA, CTA or DSA); 6. Patients with first onset or past onset without sequelae such as limb paralysis should not affect the score of this NIHSS, and mRS Score of patients with past onset should be less than 2 points; 7. Patients or family members sign informed consent. Exclusion Criteria: 1. Patients who have developed large intracranial vessel occlusion; 2. Intracranial hemorrhagic diseases in the past 3 months: cerebral hemorrhage, subarachnoid hemorrhage, etc.; 3. Non-atherosclerotic disease-related stenosis: arterial dissection, moya-moya disease, arterioinflammatory disease, etc. 4. Clotting disorders or systemic bleeding tendency or platelets less than 100,000; 5. Complicated with serious infection or liver, kidney and other serious diseases; 6. Patients with severe inability to control hypertension (systolic blood pressure \>200mmHg or diastolic blood pressure \>110mmHg); 7. Women who are pregnant, have a pregnancy plan or are breastfeeding; 8. Complicated with other serious diseases, life expectancy \< 6 months; Other conditions deemed inappropriate for participation in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
General Hospital of Northern Theater Command Shenyang China Recruiting

More General Hospital of Shenyang Military Region trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06763458 on ClinicalTrials.gov ↗ ← All trials in China